An unmet need exists for effective therapies to lower triglyceride levels in patients with residual cardiovascular risk despite optimal lipid-lowering therapies.    

The ESSENCE-TIMI 73b trial investigated the efficacy and safety of the apolipoprotein C-III RNA-targeting medicine, olezarsen, in patients with moderate hypertriglyceridaemia and elevated cardiovascular risk.  

Monthly olezarsen injections significantly reduced triglyceride levels by approximately 60% at 6 months vs. placebo and more than 80% of patients achieved normal triglyceride levels with olezarsen at 12 months.  

As we age, what and how much we eat tends to change. However, how meal timing relates to our health remains less understood. Researchers at Mass General Brigham and their collaborators studied changes to meal timing in older adults and discovered people experience gradual shifts in when they eat meals as they age. They also found characteristics that may contribute to meal timing shifts and revealed specific trajectories linked to an earlier death. The results are published in Communications Medicine.

There are currently no approved therapies for nonobstructive hypertrophic cardiomyopathy (HCM). 

The ODYSSEY-HCM trial compared the cardiac myosin inhibitor, mavacamten, with placebo in patients with symptomatic nonobstructive HCM. 

Mavacamten was not associated with significant improvements in patient-reported health status or peak oxygen consumption. 

Further subgroup analyses are in progress.